According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Individual Participant Data Meta-Analysis of Randomized Controlled Trials
The claim can be definitively tested by pooling individual-level data from all major statin RCTs (e.g., JUPITER, HPS, ASCOT, TNT, PROVE-IT) that include long-term cancer outcomes. The analysis would stratify participants by baseline LDL (<2 mmol/L vs ≥2 mmol/L) and baseline vascular risk (low, moderate, high), comparing cancer incidence and cancer-specific mortality between statin and placebo groups over ≥5 years of follow-up. Large Pragmatic Randomized Controlled Trial in Low-LDL Population
A dedicated RCT enrolling only individuals with baseline LDL <2 mmol/L and low vascular risk (e.g., no diabetes, no hypertension, no smoking) to isolate the effect of statins on cancer outcomes in this specific subgroup. Prospective Population-Based Cohort with Long-Term Cancer Surveillance
To observe cancer outcomes in real-world populations over decades, capturing statin use patterns and cancer incidence in individuals with naturally low LDL. Nested Case-Control Study within Statin RCTs
To compare cancer characteristics and timing in statin users vs. non-users who developed cancer during trials. Systematic Review with Network Meta-Analysis of Statin Types and Doses
To determine if different statins or doses have differential effects on cancer risk in low-LDL populations.